CTRI/2010/091/001346
Completed
Phase 4
Assessment of efficacy, safety and tolerability of fixed dose combination Wunder eye Cream (3% Biophytex LS 8740 and 5% Proteasyl TP LS 8657) in the treatment of Under Eye Dark Circles (Infra-orbital hyperchromia)
Glenmark Pharmaceutical limited0 sites500 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Glenmark Pharmaceutical limited
- Enrollment
- 500
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects eligible for enrolment in the study must meet all the following criteria.
- •Subjects with mild, moderate or severe under eye dark circles
- •Subjects must be 18\-50 years of age
- •Subjects must provide written informed consent and comply to the protocol
Exclusion Criteria
- •Subjects meeting any of the following criteria must not be enrolled in the clinical study.
- •Subjects not willing to discontinue all topical treatments for ?Under Eye? dark circles for 2 weeks prior to enrollment in study
- •Hypersensitivity to any ingredients of Wunder Eye cream
- •Pregnant and lactating women
- •Subjects taking Concomitant therapy\* that might interfere with the study results
- •Subjects with dermatological disorder of face that may interfere with study evaluation
- •Subjects who have undergone any surgical treatment of the face
- •\*Concomitant topical therapy in under eye area that causes hypopigmentation, includes Retinoids and Hyroquinone skin peels.
- •\*Concomitant medicines, that causes hyper pigmentation, includes Phenothiazines, Anti\-malarials (Chloroquine), Phenytoin sodium, Cytotoxic drugs, Sulphonamides.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
A clinical trial to assess the efficacy, safety and tolerability of tigecycline in adult hospitalized patients with community acquired pneumonia (CAP).Health Condition 1: null- community acquired pneumonia (CAP)CTRI/2010/091/001439Glenmark Pharmaceuticals Limited120
Active, not recruiting
Not Applicable
Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCEEUCTR2005-006071-12-ITAZIENDA OSPEDALIERA SAN CAMILLO FORLANINI276
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
Completed
Not Applicable
study on low back paiCTRI/2016/10/007348Dr Reddys Laboratories Pvt Ltd
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisEUCTR2019-002341-38-BEGM Biopharmaceuticals, Inc.150